Study provides evidence of protective link between oralmicrobiome and COVID frontiersin
). The longest possible period of time between antibiotic exposure and sample collection in this study was 4 days, and as such, we do not believe this represents a substantial confounder in this analysis.
Weaknesses of this study include a single time-point in microbiome sampling from a single center and enrollment of a limited number of patients presenting with acute COVID-19 early in the disease course. Single time-point sampling does not allow for observation of how an individual’s oropharyngeal microbiota may change over the course of the disease.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
Safety and Outcome of Revascularization Treatment in Patients With Acute Ischemic Stroke and COVID-19: The Global COVID-19 Stroke RegistryBackground and objectives: COVID-19 related inflammation, endothelial dysfunction and coagulopathy may increase the bleeding risk and lower efficacy of revascularization treatments in patients with acute ischemic stroke. We aimed to evaluate the safety and outcomes of revascularization treatments in patients with acute ischemic stroke and COVID-19. Methods: Retrospective multicenter cohort study of consecutive patients with acute ischemic stroke receiving intravenous thrombolysis (IVT) and/or endovascular treatment (EVT) between March 2020 and June 2021, tested for SARS-CoV-2 infection. With a doubly-robust model combining propensity score weighting and multivariate regression, we studied the association of COVID-19 with intracranial bleeding complications and clinical outcomes. Subgroup analyses were performed according to treatment groups (IVT-only and EVT). Results: Of a total of 15128 included patients from 105 centers, 853 (5.6%) were diagnosed with COVID-19. 5848 (38.7%) patients received IVT-only, and 9280 (61.3%) EVT (with or without IVT). Patients with COVID-19 had a higher rate of symptomatic intracerebral hemorrhage (SICH) (adjusted odds ratio [OR] 1.53; 95% CI 1.16–2.01), symptomatic subarachnoid hemorrhage (SSAH) (OR 1.80; 95% CI 1.20–2.69), SICH and/or SSAH combined (OR 1.56; 95% CI 1.23–1.99), 24-hour (OR 2.47; 95% CI 1.58–3.86) and 3-month mortality (OR 1.88; 95% CI 1.52–2.33). COVID-19 patients also had an unfavorable shift in the distribution of the modified Rankin score at 3 months (OR 1.42; 95% CI 1.26–1.60). Discussion: Patients with acute ischemic stroke and COVID-19 showed higher rates of intracranial bleeding complications and worse clinical outcomes after revascularization treatments than contemporaneous non-COVID-19 treated patients. Current available data does not allow direct conclusions to be drawn on the effectiveness of revascularization treatments in COVID-19 patients, or to establish different treatment recommendations in this subgro
Consulte Mais informação »
How long COVID is defined and measured affects prevalence estimationIn a recent study posted to the medRxiv* preprint server, researchers evaluated the prevalence of long coronavirus disease (COVID) symptoms, functional disabilities, symptoms, and pathological alterations among adults and children ≥12 weeks post-acute COVID 2019 (COVID-19).
Consulte Mais informação »
Melatonin could be a potential therapy for long-COVID symptomsA recent review published in the journal Biomolecules discussed the potential uses of melatonin in treating brain fog, and chronic fatigue syndrome or myalgic encephalomyelitis symptoms associated with long coronavirus disease (COVID)
Consulte Mais informação »
Delay in consciousness in severe cases of COVID-19 may be caused by neural hibernationAn article published in the journal PNAS provides a conceptual analysis to interpret the brain state of coronavirus disease 2019 (COVID-19) patients experiencing prolonged recovery of consciousness.
Consulte Mais informação »
The comparative risk of myocarditis, pericarditis, and myopericarditis between BNT162b2 and mRNA-1273 second dosesThe comparative risk of myocarditis, pericarditis, and myopericarditis between BNT162b2 and mRNA-1273 second doses UBC UofT vaccine vaccination myocarditis mRNA mRNAvaccine
Consulte Mais informação »